Cigna (CI), HealthSpring (HS) Clear HSR Act Hurdle in Proposed Merger
Tweet Send to a FriendGet Alerts CI Hot Sheet
Price: $67.33 -0.87%
Overall Analyst Rating:
BUY (
Down)
Dividend Yield: 0.3%
Revenue Growth %: +18.6%
Overall Analyst Rating:
BUY (
Down)Dividend Yield: 0.3%
Revenue Growth %: +18.6%
Trade CI Now!
Cigna Corporation (NYSE: CI) and HealthSpring, Inc. (NYSE: HS) have received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with Cigna’s pending acquisition of HealthSpring. The early termination of the waiting period under the Hart-Scott-Rodino Act satisfies one of the conditions for consummation of the transaction.
The transaction is expected to close during the first half of 2012 and remains subject to certain other closing conditions, including approval by HealthSpring stockholders and state regulatory approvals.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The transaction is expected to close during the first half of 2012 and remains subject to certain other closing conditions, including approval by HealthSpring stockholders and state regulatory approvals.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Bausch & Lomb near deal to sell to Valeant Pharmaceuticals (VRX) - WSJ
- Tempur-Pedic (TPX) is Now 'Tempur Sealy International'
- Echo Pharma Lowers Acceptance Threshold in Elan (ELN) Bid to 50%
Create E-mail Alert Related Categories
Corporate News, Mergers and Acquisitions
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
